Actuate Therapeutics, Inc. (ACTU)
NASDAQ: ACTU · Real-Time Price · USD
2.860
-0.340 (-10.63%)
At close: Mar 6, 2026, 4:00 PM EST
2.870
+0.010 (0.35%)
After-hours: Mar 6, 2026, 7:58 PM EST
Actuate Therapeutics Employees
Actuate Therapeutics had 10 employees as of December 31, 2024. The number of employees increased by 5 or 100.00% compared to the previous year.
Employees
10
Change (1Y)
5
Growth (1Y)
100.00%
Revenue / Employee
n/a
Profits / Employee
-$2,411,999
Market Cap
66.48M
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 10 | 5 | 100.00% |
| Dec 31, 2023 | 5 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| TScan Therapeutics | 148 |
| XBiotech | 88 |
| InflaRx | 74 |
| Mereo BioPharma Group | 36 |
| eXoZymes | 31 |
| Q32 Bio | 26 |
| Annovis Bio | 15 |
| MediciNova | 13 |
ACTU News
- 11 days ago - Actuate Therapeutics to Present at the Oppenheimer 36th Annual Healthcare Life Sciences Conference - GlobeNewsWire
- 7 weeks ago - Actuate Therapeutics Reports Positive Follow-Up Data from its Randomized Controlled Phase 2 Trial Demonstrating Extended Long-Term Overall Survival Benefit with Elraglusib Plus Chemotherapy for Metastatic Pancreatic Cancer in Oral Presentation at ASCO GI 2026 - GlobeNewsWire
- 2 months ago - Actuate Therapeutics Announces Positive Patient Outcomes from Phase 1 Trial in Difficult-to-Treat Refractory Pediatric Cancers - GlobeNewsWire
- 2 months ago - Actuate Therapeutics Phase 2 Metastatic Pancreatic Cancer Data Selected for Oral and Poster Presentation at ASCO GI 2026 - GlobeNewsWire
- 5 months ago - Actuate Therapeutics Provides FDA with Updated Clinical Data Package to Support Planned Regulatory Interactions with FDA and EMA Over the Coming Months - GlobeNewsWire
- 6 months ago - Actuate Therapeutics Announces Pricing of $15.0 Million Public Offering of Common Stock - GlobeNewsWire
- 6 months ago - Actuate Therapeutics Announces Proposed Public Offering of Common Stock - GlobeNewsWire
- 7 months ago - Actuate Therapeutics To Collaborate with Incyte Corporation and the University of Pittsburgh on Clinical Trial of Elraglusib in Combination with Retifanlimab and mFOLFIRINOX in Patients with Advanced Pancreatic Cancer - GlobeNewsWire